Your browser doesn't support javascript.
loading
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Reisinger, Emil C; Tschismarov, Roland; Beubler, Eckhard; Wiedermann, Ursula; Firbas, Christa; Loebermann, Micha; Pfeiffer, Andrea; Muellner, Matthias; Tauber, Erich; Ramsauer, Katrin.
Afiliação
  • Reisinger EC; Rostock University Medical Center, Rostock, Germany. Electronic address: emil.reisinger@uni-rostock.de.
  • Tschismarov R; Themis, Vienna, Austria.
  • Beubler E; Otto Loewi Research Center, Medical University Graz, Graz, Austria.
  • Wiedermann U; Institute of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Vienna, Austria.
  • Firbas C; Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria.
  • Loebermann M; Rostock University Medical Center, Rostock, Germany.
  • Pfeiffer A; Themis, Vienna, Austria.
  • Muellner M; Themis, Vienna, Austria.
  • Tauber E; Themis, Vienna, Austria.
  • Ramsauer K; Themis, Vienna, Austria.
Lancet ; 392(10165): 2718-2727, 2019 12 22.
Article em En | MEDLINE | ID: mdl-30409443

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Vírus Chikungunya / Febre de Chikungunya Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Vírus Chikungunya / Febre de Chikungunya Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido